Patents by Inventor Qunli Xu
Qunli Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240123806Abstract: The electric all-terrain vehicle includes a vehicle frame, a motor, a gearbox, a cargo compartment, a battery pack, a handle assembly and a walking wheel. The motor is arranged on the vehicle frame and located at a rear end of the vehicle frame. The gearbox is arranged on the vehicle frame and located on a first side of the motor, and the gearbox is connected with the motor. The cargo compartment is arranged on the vehicle frame and located above the motor and the gearbox. The battery pack is mounted on a bracket to provide power for the electric all-terrain vehicle. The handle assembly is arranged on the cargo compartment and allows an adjustment of the handle assembly to lock or unlock the cargo compartment from the vehicle frame. The walking wheel is arranged on the vehicle frame and includes a rear wheel connected with the gearbox.Type: ApplicationFiled: December 7, 2023Publication date: April 18, 2024Applicant: Greenworks (Jiangsu) Co., Ltd.Inventors: Qunli WEI, Fei ZHU, Jiafu XUE, Mi DING, Shiyuan DING, Baogui WU, Yueyue XU
-
Publication number: 20240016795Abstract: Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed. In some methods, the AR-positive forms of cancer may be breast cancer, including triple negative forms, hormone receptor positive forms, and HER2-positive forms. In other methods, the AR-positive forms of cancer may be prostate cancer, including metastatic castration resistant prostate cancer. In some embodiments, methods of treating prostate cancer comprise the step of administering to a patient in need thereof the compound (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 22, 2023Publication date: January 18, 2024Inventors: Sylvie GUICHARD, Maureen CALIGIURI, Anna ERICSSON, Qunli XU, Hesham MOHAMED
-
Patent number: 11801243Abstract: Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed. In some methods, the AR-positive forms of cancer may be breast cancer, including triple negative forms, hormone receptor positive forms, and HER2-positive forms. In other methods, the AR-positive forms of cancer may be prostate cancer, including metastatic castration resistant prostate cancer. In some embodiments, methods of treating prostate cancer comprise the step of administering to a patient in need thereof the compound (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 23, 2021Date of Patent: October 31, 2023Assignee: Forma Therapeutics, Inc.Inventors: Sylvie Guichard, Maureen Caligiuri, Anna Ericsson, Qunli Xu, Hesham Mohamed
-
Publication number: 20230321097Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).Type: ApplicationFiled: November 17, 2022Publication date: October 12, 2023Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
-
Publication number: 20220088005Abstract: Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed. In some methods, the AR-positive forms of cancer may be breast cancer, including triple negative forms, hormone receptor positive forms, and HER2-positive forms. In other methods, the AR-positive forms of cancer may be prostate cancer, including metastatic castration resistant prostate cancer. In some embodiments, methods of treating prostate cancer comprise the step of administering to a patient in need thereof the compound (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 23, 2021Publication date: March 24, 2022Inventors: Sylvie GUICHARD, Maureen CALIGIURI, Anna ERICSSON, Qunli XU, Hesham MOHAMED
-
Publication number: 20200316067Abstract: The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering a Raf inhibitor in combination with a taxane. The present disclosure relates to methods of treating a subject suffering from cancer, comprising administering to the subject: (i) a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and (ii) a taxane or a pharmaceutically acceptable salt thereof; the amount of the Raf kinase inhibitor and taxane or a pharmaceutically acceptable salt thereof is such that the combination thereof is therapeutically effective in the treatment of the cancer.Type: ApplicationFiled: June 1, 2020Publication date: October 8, 2020Inventors: Viviana Bozon, Katherine M. Galvin, Rachael L. Brake, Qunli Xu, Karuppiah Kannan
-
Publication number: 20200147080Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).Type: ApplicationFiled: July 23, 2019Publication date: May 14, 2020Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
-
Patent number: 10426782Abstract: The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.Type: GrantFiled: March 26, 2015Date of Patent: October 1, 2019Assignee: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Rachael L. Brake, Viviana Bozon, Ching-Kuo J. Chow, James C. Dinunzio, Katherine M. Galvin, Karuppiah Kannan, Yuki Kodono, Qunli Xu
-
Patent number: 10406158Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).Type: GrantFiled: April 2, 2018Date of Patent: September 10, 2019Assignee: Verastem, Inc.Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
-
Publication number: 20190117652Abstract: The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering a Raf inhibitor in combination with a taxane. The present disclosure relates to methods of treating a subject suffering from cancer, comprising administering to the subject: (i) a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and (ii) a taxane or a pharmaceutically acceptable salt thereof; the amount of the Raf kinase inhibitor and taxane or a pharmaceutically acceptable salt thereof is such that the combination thereof is therapeutically effective in the treatment of the cancer.Type: ApplicationFiled: December 22, 2015Publication date: April 25, 2019Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Viviana BOZON, Katherine M. GALVIN, Rachael L. BRAKE, Qunli XU, Karuppiah KANNAN
-
Publication number: 20190046531Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).Type: ApplicationFiled: April 2, 2018Publication date: February 14, 2019Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
-
Patent number: 9962385Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).Type: GrantFiled: February 6, 2015Date of Patent: May 8, 2018Assignee: Verastem, Inc.Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
-
Publication number: 20170173033Abstract: The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.Type: ApplicationFiled: March 26, 2015Publication date: June 22, 2017Inventors: Rachael L. BRAKE, Viviana BOZON, Ching-Kuo J. CHOW, James C. DINUNZIO, Katherine M. GALVIN, Karuppiah KANNAN, Yuki KODONO, Qunli XU
-
Publication number: 20160346282Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).Type: ApplicationFiled: February 6, 2015Publication date: December 1, 2016Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
-
Patent number: 6545128Abstract: The present invention provides substantially purified nucleic acid molecules encoding Bax inhibitor protein-1 (BI-1; SEQ ID NO: 1) or Bax inhibitor protein-2 (BI-2; SEQ ID NO: 4), nucleic acid molecules complementary thereto (SEQ ID NO: 2 and SEQ ID NO: 5, respectively), portions of such nucleic acid molecules, vectors containing the nucleic acid molecules, and host cells containing the vectors. The invention also provides methods of using such nucleic acid molecules to identify the presence of a nucleic acid molecule encoding a Bax inhibitor protein in a sample or to increase or decrease the level of expression of a Bax inhibitor protein in a cell. In addition, the invention provides substantially purified BI-1 (SEQ ID NO: 3) and BI-2 (SEQ ID NO: 6) polypeptides, portions of such polypeptides, and antibodies specific for BI-1 or BI-2.Type: GrantFiled: July 6, 2000Date of Patent: April 8, 2003Assignee: The Burnham InstituteInventors: John C. Reed, Qunli Xu
-
Patent number: 6130317Abstract: The present invention provides substantially purified nucleic acid molecules encoding Bax inhibitor protein-1 (BI-1; SEQ ID NO: 1) or Bax inhibitor protein-2 (BI-2; SEQ ID NO: 4), nucleic acid molecules complementary thereto (SEQ ID NO: 2 and SEQ ID NO: 5, respectively), portions of such nucleic acid molecules, vectors containing the nucleic acid molecules, and host cells containing the vectors. The invention also provides methods of using such nucleic acid molecules to identify the presence of a nucleic acid molecule encoding a Bax inhibitor protein in a sample or to increase or decrease the level of expression of a Bax inhibitor protein in a cell. In addition, the invention provides substantially purified BI-1 (SEQ ID NO: 3) and BI-2 (SEQ ID NO: 6) polypeptides, portions of such polypeptides, and antibodies specific for BI-1 or BI-2.Type: GrantFiled: July 15, 1998Date of Patent: October 10, 2000Assignee: The Burnham InstituteInventors: John C. Reed, Qunli Xu
-
Patent number: 5837838Abstract: The present invention provides substantially purified nucleic acid molecules encoding Bax inhibitor protein-1 (BI-1; SEQ ID NO: 1) or Bax inhibitor protein-2 (BI-2; SEQ ID NO: 4), nucleic acid molecules complementary thereto (SEQ ID NO: 2 and SEQ ID NO: 5, respectively), portions of such nucleic acid molecules, vectors containing the nucleic acid molecules, and host cells containing the vectors. The invention also provides methods of using such nucleic acid molecules to identify the presence of a nucleic acid molecule encoding a Bax inhibitor protein in a sample or to increase or decrease the level of expression of a Bax inhibitor protein in a cell. In addition, the invention provides substantially purified BI-1 (SEQ ID NO: 3) and BI-2 (SEQ ID NO: 6) polypeptides, portions of such polypeptides, and antibodies specific for BI-1 or BI-2.Type: GrantFiled: March 14, 1997Date of Patent: November 17, 1998Assignee: The Burnham InstituteInventors: John C. Reed, Qunli Xu